RxDoctor Payments Data

Keith Cochran, MD

Neurology · Santa Fe Springs, CANPI 1508252651

Payments from drug & device makers

$938in general payments, 2019–2025

Across 33 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$311
  • Novartis$298
  • Medtronic$179
  • AbbVie$135
  • UCB, Inc.$15

What the payments were for

  • Food & beverage$81287%
  • Education$12613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.9$311
Novartis14$298
Medtronic(2 entities)4$179
AbbVie5$135
UCB, Inc.1$15

How this compares

$938 in reported general payments places this provider in the 45th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$89,820
Medicare patients
193
Services billed
5,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate61$371,280
AustedoDeutetrabenazine52$344,148
IngrezzaValbenazine Tosylate20$131,998
NeuproRotigotine69$71,280
BotoxOnabotulinumtoxina40$40,896
RytaryCarbidopa/Levodopa22$26,879
Carbidopa-LevodopaCarbidopa/Levodopa674$26,676
Rasagiline Mesylate69$16,214
EliquisApixaban13$12,915
Memantine Hcl230$12,517
Rivastigmine56$12,397
Carbidopa-Levodopa ErCarbidopa/Levodopa101$8,319
AmantadineAmantadine Hcl137$6,716
Entacapone31$6,349
Primidone163$6,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$311$344,14852 claims
UCB, Inc.Neupro$15$71,28069 claims
AbbVieBotox$135$40,89640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,996 neurology providers in California.

Other neurology in Santa Fe Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →